NASDAQ:INGN

Inogen - INGN Stock Forecast, Price & News

$32.01

+1.01 (+3.26%)

(As of 08/18/2022 03:33 PM ET)

Add

Compare

Today's Range: $30.41
▼
$32.01
50-Day Range: $23.48
▼
$31.80
52-Week Range: $22.51
▼
$63.05

Volume: 3,514 shs
Average Volume: 176,937 shs
Market Capitalization: $732.07 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $41.00

Inogen MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 28.7% Upside
$41.00 Price Target
Short Interest: Healthy
3.93% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.00
Upright™ Environmental Score
News Sentiment: 0.93
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.64) to ($0.86) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

429th out of 1,119 stocks

Surgical Appliances & Supplies Industry

10th out of 23 stocks

3.1

Analyst's Opinion

Consensus Rating
Inogen has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.00, Inogen has a forecasted upside of 28.7% from its current price of $31.85.
Amount of Analyst Coverage
Inogen has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.93% of the float of Inogen has been sold short.
Short Interest Ratio / Days to Cover
Inogen has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Inogen has recently decreased by 5.99%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Inogen does not currently pay a dividend.
Dividend Growth
Inogen does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Inogen has received a 49.08% net impact score from Upright. Inogen seems to create the most significant positive value in categories "Taxes", "Physical diseases", and "Jobs". The positive contribution in the "Physical diseases" impact category is driven by its "Medical ventilators" product. See details.
Environmental Sustainability
The Environmental Impact score for Inogen is -1.00.

2.7

News and Social Media Coverage

News Sentiment
Inogen has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Inogen this week, compared to 3 articles on an average week.
MarketBeat Follows
Only 1 people have added Inogen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inogen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.19% of the stock of Inogen is held by insiders.
Percentage Held by Institutions
96.01% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Inogen are expected to grow in the coming year, from ($1.64) to ($0.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inogen is -25.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inogen is -25.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inogen has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Inogen (NASDAQ:INGN) Stock

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Inogen Price Performance

Shares of Inogen stock opened at $31.00 on Thursday. Inogen has a 52-week low of $22.51 and a 52-week high of $63.05. The firm has a market capitalization of $708.85 million, a PE ratio of -24.80 and a beta of 1.02. The company's fifty day moving average price is $26.89 and its two-hundred day moving average price is $28.42.

Inogen (NASDAQ:INGN - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The medical technology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.24. The firm had revenue of $103.38 million during the quarter, compared to analyst estimates of $100.64 million. Inogen had a negative net margin of 8.03% and a negative return on equity of 5.35%. The company's quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.22 earnings per share. Analysts predict that Inogen will post -1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on INGN shares. Stifel Nicolaus reduced their price objective on Inogen from $40.00 to $30.00 in a research report on Monday, May 9th. StockNews.com upgraded shares of Inogen from a "sell" rating to a "hold" rating in a research report on Friday, August 5th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, Inogen has a consensus rating of "Hold" and an average target price of $41.00.

Receive INGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter.

INGN Stock News Headlines

August 15, 2022 | americanbankingnews.com

Inogen, Inc. (NASDAQ:INGN) Receives $41.00 Average PT from Brokerages

August 9, 2022 | nasdaq.com

Is It Time To Consider Buying Inogen, Inc. (NASDAQ:INGN)? - Nasdaq

August 9, 2022 | seekingalpha.com

Inogen, Inc. (INGN) CEO Nabil Shabshab on Q2 2022 Results - Earnings Call Transcript

August 8, 2022 | finance.yahoo.com

Portable Oxygen Generator Market Worth USD 2421.67 million by 2027 | Drivers, Trends, Opportunities, Challenges | Developments, Revenue, Growth Rate | Key Players, Top Countries, Types, Applications - Yahoo Finance

August 7, 2022 | americanbankingnews.com

StockNews.com Upgrades Inogen (NASDAQ:INGN) to Hold

August 6, 2022 | finance.yahoo.com

Is It Too Late To Consider Buying Inogen, Inc. (NASDAQ:INGN)?

August 4, 2022 | finance.yahoo.com

Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

August 4, 2022 | businesswire.com

Inogen Announces Second Quarter 2022 Financial Results - Business Wire

August 4, 2022 | finance.yahoo.com

Inogen Announces Second Quarter 2022 Financial Results

August 1, 2022 | nasdaq.com

Inogen (INGN) Surges 5.1%: Is This an Indication of Further Gains? - Nasdaq

August 1, 2022 | finance.yahoo.com

Inogen (INGN) Surges 5.1%: Is This an Indication of Further Gains?

July 12, 2022 | benzinga.com

Oxygen Concentrators Global Market Opportunities And Strategies To 2031: COVID-19 Implications And Growth - Benzinga

July 12, 2022 | finance.yahoo.com

Oxygen Concentrators Global Market Opportunities And Strategies To 2031: COVID-19 Implications And Growth - Yahoo Finance

July 7, 2022 | finance.yahoo.com

Inogen to Announce Second Quarter 2022 Financial Results on August 4, 2022

July 6, 2022 | finance.yahoo.com

Femasys Inc. Announces Existing Board Member Charles Larsen as Chairperson of the Board - Yahoo Finance

June 22, 2022 | nasdaq.com

Here's Why You Should Hold on to Inogen (INGN) Stock For Now - Nasdaq

June 16, 2022 | seekingalpha.com

Inogen: Seasonal FCF, Tightening Margins, Supply Chain Headwinds

June 14, 2022 | benzinga.com

Short Volatility Alert: Inogen, Inc. - Benzinga - Benzinga

May 18, 2022 | businesswire.com

Inogen Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning - Business Wire

May 18, 2022 | finance.yahoo.com

Inogen Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning

May 13, 2022 | nasdaq.com

Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat - Nasdaq

May 13, 2022 | finance.yahoo.com

Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat

May 9, 2022 | benzinga.com

Stifel Maintains Hold on Inogen, Lowers Price Target to $30 - Benzinga - Benzinga

May 9, 2022 | benzinga.com

Stifel Maintains Hold Rating for Inogen: Here's What You Need To Know - Benzinga - Benzinga

May 8, 2022 | seekingalpha.com

Inogen's (INGN) CEO Nabil Shabshab on Q1 2022 Results - Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive INGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter.

INGN Company Calendar

Last Earnings: 8/04/2022
Today: 8/18/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INGN
CUSIP: N/A
CIK: 1294133
Web: www.inogen.com
Phone: (805) 562-0500
Fax: N/A
Employees: 1,021
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $41.00
High Stock Price Forecast: $47.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +28.1%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,330,000.00
Net Margins: -8.03%
Pretax Margin: -5.19%
Return on Equity: -5.35%
Return on Assets: -4.06%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.32
Quick Ratio: 4.75

Sales & Book Value

Annual Sales: $358 million
Price / Sales: 2.04
Cash Flow: $0.68 per share
Price / Cash Flow: 47.25
Book Value: $15.59 per share
Price / Book: 2.05

Miscellaneous

Outstanding Shares: 22,870,000
Free Float: 22,594,000
Market Cap: $732.07 million
Optionable: Optionable
Beta: 1.02

Key Executives

Mr. Nabil Shabshab (Age 57)
CEO, Pres & Director
Comp: $3.24M
Ms. Alison Perry Bauerlein (Age 41)
Co-Founder
Comp: $621.06k
Mr. Bart Sanford (Age 56)
Exec. VP of Operations
Comp: $558.22k
Dr. Stanislav Glezer M.D. (Age 49)
MBA, Exec. VP & CTO
Comp: $628.3k
Mr. George J. Parr (Age 51)
Exec. VP & Chief Commercial Officer
Comp: $799.95k
Ms. Kristin A. Caltrider (Age 54)
Exec. VP, CFO & Treasurer
Ms. Agnes Lee
Sr. VP of Investor Relations & Strategic Planning
Mr. Jason Somer (Age 54)
Exec. VP, Gen. Counsel & Corp. Sec.
Ms. Jennifer Yi Boyer
Exec. VP & Chief HR Officer
Mr. Matthew Pigeon
Investor Relations Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INGN Stock - Frequently Asked Questions

Should I buy or sell Inogen stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings or view top-rated stocks.
What is Inogen's stock price forecast for 2022?: 4 brokers have issued 12 month price targets for Inogen's stock. Their INGN share price forecasts range from $30.00 to $47.00. On average, they expect the company's stock price to reach $41.00 in the next year. This suggests a possible upside of 32.3% from the stock's current price.
View analysts price targets for INGN or view top-rated stocks among Wall Street analysts.
How have INGN shares performed in 2022?: Inogen's stock was trading at $34.00 at the beginning of 2022. Since then, INGN stock has decreased by 8.8% and is now trading at $31.00.
View the best growth stocks for 2022 here.
When is Inogen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our INGN earnings forecast.
How were Inogen's earnings last quarter?: Inogen, Inc. (NASDAQ:INGN) posted its earnings results on Thursday, August, 4th. The medical technology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.24. The medical technology company had revenue of $103.38 million for the quarter, compared to the consensus estimate of $100.64 million. Inogen had a negative net margin of 8.03% and a negative trailing twelve-month return on equity of 5.35%. The company's revenue for the quarter was up 1.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.22 EPS.
What guidance has Inogen issued on next quarter's earnings?: Inogen updated its third quarter 2022 earnings guidance on Thursday, August, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $97.00 million-$100.00 million, compared to the consensus revenue estimate of $98.77 million.

What is Scott Wilkinson's approval rating as Inogen's CEO?: 70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Inogen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).
What is Inogen's stock symbol?: Inogen trades on the NASDAQ under the ticker symbol "INGN."
Who are Inogen's major shareholders?: Inogen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State Street Corp (3.74%), Sio Capital Management LLC (2.30%), FMR LLC (1.45%), Renaissance Technologies LLC (1.38%), Northern Trust Corp (1.00%) and Meros Investment Management LP (0.82%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Loren L Mcfarland, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends.
How do I buy shares of Inogen?: Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Inogen's stock price today?: One share of INGN stock can currently be purchased for approximately $31.00.
How much money does Inogen make?: Inogen (NASDAQ:INGN) has a market capitalization of $708.85 million and generates $358 million in revenue each year. The medical technology company earns $-6,330,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.
How many employees does Inogen have?: The company employs 1,021 workers across the globe.
How can I contact Inogen?: Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net.

This page (NASDAQ:INGN) was last updated on 8/18/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Inogen - INGN Stock Forecast, Price & News

Inogen MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month